First-line pazopanib in patients with metastatic epithelioid hemangioendothelioma: a retrospective single-center analysis
This is the first study to systematically report survival outcomes for PAZ as a first-line treatment in patients with metastatic EHE. PAZ is active and safe in patients with metastatic EHE and may be considered as an alternative to sirolimus for specific patient subgroups. RECIST criteria should be questioned for evaluation of treatment response in EHE.
Authors
- Hans Roland Dürr (ORCID: https://orcid.org/0000-0002-1347-1173)
- Michael von Bergwelt‐Baildon (ORCID: https://orcid.org/0000-0002-1952-052X)
- Anton Burkhard‐Meier (ORCID: https://orcid.org/0009-0002-9801-3530)
- Luc M. Berclaz (ORCID: https://orcid.org/0000-0003-4405-138X)
- Alexander Klein (ORCID: https://orcid.org/0000-0002-5562-9872)
- Dorit Di Gioia
- Vindi Jurinović
- Wolfgang G. Kunz (ORCID: https://orcid.org/0000-0002-5021-1952)
- Andreas Möck (ORCID: https://orcid.org/0000-0002-3332-9166)
- Thomas Knösel (ORCID: https://orcid.org/0000-0002-1822-0197)
- Markus Albertsmeier (ORCID: https://orcid.org/0000-0002-5028-5062)
- Árpád Pusztai
- Lars H. Lindner (ORCID: https://orcid.org/0000-0003-3708-8264)
- Vera Valerie Rechenauer
- Michael Hoberger
- Michael Völkl
Institutions
- LMU Klinikum (DE)
- Zimmer Biomet (Germany) (DE)
- Centre de Coopération Universitaire Franco-Bavarois (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-04-26
- DOI
- https://doi.org/10.1007/s00432-025-06208-8
- Citations
- 4
- Primary Topic
- Vascular Tumors and Angiosarcomas
- Type
- article
- Field-Weighted Citation Impact
- 4.18